NSE: DIVISLAB · Healthcare · Pharmaceuticals · Market cap ₹3,06,829 Cr
· Prev close ₹11,097.00 · Volume 24.41 L · 52W ₹5,648–11,558
Day range for 9 Nov not in the price history yet · 8 Nov ₹10,669.00–11,194.00
Last 4 quarters: profit +35.3% on the 4 beforeShare price +18.6% in a month
If profit compounds at 0.0% (CAGR) and the stock ends at 25×, buying at ₹11,558 returns about −12.1% CAGR over 10 years.
| Growth assumption | Profit growth (CAGR) | Return, 10Y CAGR |
|---|---|---|
| Yours | 0.0% | −12.1% |
| Delivered FY22–26 | −3.5% | −15.2% |
| Net profit, last 4 quarters vs the 4 before | 35.3% | 18.9% |
| Half the delivered pace | −1.7% | −13.7% |
Delivered FY22–26 CAGR −3.5%
This is an exit-multiple calculation, not a discounted cash flow. Inputs: EPS for the 4 quarters Dec 2025 to Sep 2026 ₹126.73, price ₹11,558.00 (9 Nov 2026, 2:47 pm IST price). Formula: return = (EPS × exit P/E ÷ price)^(1/10) × (1 + growth) − 1. Net profit growth is applied to EPS, so the share count is held constant. A profit fall of 100% or more has no rate and is left blank. Dividends ignored. Arithmetic, not a forecast.